Ubs Asset Management Americas Inc Apellis Pharmaceuticals, Inc. Transaction History

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 191,065 shares of APLS stock, worth $6.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

191,065

Previous 208,184 8.22%

Holding current value

$6.3 Million

Previous $7.99 Million 31.0%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$28.84 - $41.15 $493,711 - $704,446	-17,119 Reduced 8.22%	191,065 $5.51 Million
Q2 2024 Aug 13, 2024	BUY	$38.07 - $59.71 $2.62 Million - $4.11 Million	68,859 Added 49.42%	208,184 $7.99 Million
Q1 2024 May 15, 2024	SELL	$55.39 - $72.47 $135,317 - $177,044	-2,443 Reduced 1.72%	139,325 $8.19 Million
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $155,170 - $270,817	-4,178 Reduced 2.86%	141,768 $8.49 Million
Q3 2023 Nov 13, 2023	BUY	$23.65 - $89.22 $1.09 Million - $4.12 Million	46,142 Added 46.23%	145,946 $5.55 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $1.15 Million - $1.66 Million	24,718 Added 32.92%	99,804 $6.58 Million
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $256,326 - $361,845	5,928 Added 8.57%	75,086 $3.88 Million
Q3 2022 Nov 14, 2022	SELL	$44.76 - $69.66 $12.6 Million - $19.7 Million	-282,466 Reduced 80.33%	69,158 $4.72 Million
Q2 2022 Aug 12, 2022	SELL	$35.07 - $59.21 $1.35 Million - $2.28 Million	-38,516 Reduced 9.87%	351,624 $15.9 Million
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $583,884 - $891,139	16,466 Added 4.41%	390,140 $19.8 Million
Q4 2021 Feb 14, 2022	BUY	$30.74 - $49.16 $5.22 Million - $8.34 Million	169,684 Added 83.18%	373,674 $17.7 Million
Q3 2021 Nov 15, 2021	SELL	$31.4 - $69.84 $267,685 - $595,386	-8,525 Reduced 4.01%	203,990 $6.72 Million
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $6.39 Million - $10.1 Million	156,256 Added 277.74%	212,515 $13.4 Million
Q1 2021 May 14, 2021	SELL	$40.8 - $57.39 $354,470 - $498,604	-8,688 Reduced 13.38%	56,259 $2.41 Million
Q4 2020 Mar 01, 2021	SELL	$30.79 - $57.2 $58,747 - $109,137	-1,908 Reduced 2.85%	64,947 $3.71 Million
Q3 2020 Nov 13, 2020	BUY	$25.89 - $33.65 $37,048 - $48,153	1,431 Added 2.19%	66,855 $2.02 Million
Q2 2020 Aug 14, 2020	BUY	$24.8 - $38.49 $455,898 - $707,561	18,383 Added 39.08%	65,424 $2.14 Million
Q1 2020 May 15, 2020	BUY	$17.91 - $44.33 $191,457 - $473,887	10,690 Added 29.41%	47,041 $1.26 Million
Q4 2019 Feb 14, 2020	BUY	$22.1 - $30.8 $91,339 - $127,296	4,133 Added 12.83%	36,351 $1.11 Million
Q3 2019 Nov 14, 2019	BUY	$24.09 - $32.18 $440,654 - $588,636	18,292 Added 131.35%	32,218 $776,000
Q2 2019 Aug 15, 2019	BUY	$18.0 - $25.34 $250,668 - $352,884	13,926 New	13,926 $0

Others Institutions Holding APLS

# of Institutions

308

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.62B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Apellis Pharmaceuticals, Inc. Transaction History